Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 11/20 | 0.60 |
| ▸ | MAPT | P10636 | 3/20 | 0.53 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.52 |
| ▸ | CKS1B | P61024 | 2/20 | 0.50 |
| ▸ | SKP1 | P63208 | 2/20 | 0.50 |
| ▸ | SKP2 | Q13309 | 2/20 | 0.50 |
| ▸ | ACHE | P22303 | 1/20 | 0.48 |
| ▸ | PANK3 | Q9H999 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15205453 | 0.95 | GPR119 (0.56) | GPR119MAPTPTPN11CKS1BSKP1 | |
| SCHEMBL3486393 | 0.88 | GPR119 (0.75) | GPR119 | |
| SCHEMBL7090347 | 0.87 | GPR119 (0.62) | GPR119MAPTPTPN11CKS1BSKP1 | |
| SCHEMBL24964179 | 0.87 | GPR119 (0.61) | GPR119MAPTPTPN11CKS1BSKP1 | |
| SCHEMBL1447940 | 0.87 | GPR119 (0.65) | GPR119MAPTPTPN11CKS1BSKP1 | |
| SCHEMBL13009471 | 0.86 | GPR119 (0.60) | GPR119MAPTPTPN11CKS1BSKP1 | |
| SCHEMBL18373803 | 0.86 | GPR119 (0.60) | GPR119MAPTPTPN11CKS1BSKP1 | |
| SCHEMBL22725112 | 0.86 | GPR119 (0.60) | GPR119MAPTPTPN11CKS1BSKP1 | |
| SCHEMBL21159159 | 0.86 | GPR119 (0.60) | GPR119MAPTPTPN11CKS1BSKP1 | |
| SCHEMBL594427 | 0.86 | GPR119 (0.60) | GPR119MAPTPTPN11CKS1BSKP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 305 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4747248-A1 | COMPOUNDS FOR USE IN A METHOD OF TARGETED PROTEIN DEGRADATION | Institute of Cancer Research: Royal Cancer Hospital (The) (GB) | 2026-05-27 | — | — | EP | disclosed |
| US-12624043-B2 | Compositions useful for treating disorders related to kit | BLUEPRINT MEDICINES CORPORATION (US) | 2026-05-12 | — | — | US | disclosed |
| EP-4692076-A1 | HIV INHIBITOR COMPOUNDS | Gilead Sciences, Inc. (US) | 2026-02-11 | — | — | EP | disclosed |
| US-20260034220-A1 | ANTI-CEA IMMUNOCONJUGATES, AND USES THEREOF | BOLT BIOTHERAPEUTICS, INC. (US) | 2026-02-05 | — | — | US | disclosed |
| US-12479853-B2 | HIV inhibitor compounds | GILEAD SCIENCES, INC. (US) | 2025-11-25 | — | — | US | disclosed |
| EP-4634169-A1 | 3-FLUORO-4-HYDROXYBENZMIDE-CONTAINING INHIBITORS AND/OR DEGRADERS AND USES THEREOF | Pfizer Inc. (US) | 2025-10-22 | — | — | EP | disclosed |
| EP-3909949-B1 | ATAZANAVIR (ATV) ANALOGUES FOR TREATING HIV INFECTIONS | GILEAD SCIENCES INC (US) | 2025-10-15 | — | — | EP | disclosed |
| US-12421240-B2 | Hydropyrazino[1,2-d][1,4]diazepine compounds for the treatment of autoimmune disease | HOFFMANN-LA ROCHE INC. (US) | 2025-09-23 | — | — | US | disclosed |
| US-12398130-B2 | Acid addition salts of piperazine derivatives | ASCENEURON SA (CH) | 2025-08-26 | — | — | US | disclosed |
| US-20250127913-A1 | BIFUNCTIONAL FOLATE RECEPTOR BINDING COMPOUNDS | LYCIA THERAPEUTICS, INC. | 2025-04-24 | — | — | US | disclosed |
| US-6809100-B2 | 2-(4-(4-FURAN-2-YLPHENYL)PIPERAZINE-1-SULFONYLMETHYL)-N-HYDROXY -3-METHYLBUTYRAMIDE, FOR EXAMPLE; TREATMENT OF CANCER, INFLAMMATION, OR AN AUTOIMMUNE, INFECTIOUS OR OCULAR DISEASE | DARWIN DISCOVERY LTD. (GB) | 2004-10-26 | — | — | US | disclosed |
| US-20040180901-A1 | Arylpiperazines and arylpiperidines and their use as metalloproteinase inhibiting agents | ASTRAZENECA AB (SE) | 2004-09-16 | — | — | US | disclosed |
| US-6787536-B2 | A HYDROXAMIC ACID COMPOUND CONTAINING HETEROAROMATIC RING ATTACHED TO SULFONYL GROUP THROUGH NITROGEN ATOM, INHIBITOR OF MATRIX METALLOPRETEINASE, USEFUL FOR TREATING DEGENERATIVE DISEASES AND CERTAIN CANCER | DARWIN DISCOVERY LIMITED (GB) | 2004-09-07 | — | — | US | disclosed |
| EP-1417181-A1 | ARYLPIPERAZINES AND ARYLPIPERIDINES AND THEIR USE AS METALLOPROTEINASE INHIBITING AGENTS | AstraZeneca AB (SE) | 2004-05-12 | — | — | EP | disclosed |
| US-20030216404-A1 | Hydroxamic acid derivatives | HANNAH DUNCAN ROBERT (GB) | 2003-11-20 | — | — | US | disclosed |
| EP-1282614-B1 | HYDROXAMIC ACID DERIVATIVES | DARWIN DISCOVERY LTD (GB) | 2003-11-12 | — | — | EP | disclosed |
| WO-2003014092-A1 | ARYLPIPERAZINES AND ARYLPIPERIDINES AND THEIR USE AS METALLOPROTEINASE INHIBITING AGENTS | ASTRAZENECA AB (SE) | 2003-02-20 | — | — | WO | disclosed |
| EP-1282614-A1 | HYDROXAMIC ACID DERIVATIVES | Darwin Discovery Limited (GB) | 2003-02-12 | — | — | EP | disclosed |
| US-20020037900-A1 | Hydroxamic acid derivatives | DARWIN DISCOVERY LIMITED (GB) | 2002-03-28 | — | — | US | disclosed |
| WO-2001087870-A1 | HYDROXAMIC ACID DERIVATIVES | DARWIN DISCOVERY LIMITED (GB) | 2001-11-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12421240-B2 | Hydropyrazino[1,2-d][1,4]diazepine compounds for the treatment of autoimmune disease | HRH3, HRH4, HRH2 | GPR119 1257/4885MAPT 3015/4885PTPN11 2081/4885 |
| US-20040180901-A1 | Arylpiperazines and arylpiperidines and their use as metalloproteinase inhibiting agents | MMP13, MMP3, MMP2 | GPR119 867/4885MAPT 4534/4885PTPN11 1324/4885 |
| US-12624043-B2 | Compositions useful for treating disorders related to kit | KIT, RET, SLC26A4 | GPR119 2346/4885MAPT 51/4885PTPN11 1855/4885 |
| US-12479853-B2 | HIV inhibitor compounds | NFATC1, SAMHD1, CCR5 | GPR119 2624/4885MAPT 1456/4885PTPN11 3520/4885 |
| US-20250127913-A1 | BIFUNCTIONAL FOLATE RECEPTOR BINDING COMPOUNDS | FOLR1, FOLR2, FOLH1 | GPR119 527/4885MAPT 3131/4885PTPN11 2101/4885 |
| US-20260034220-A1 | ANTI-CEA IMMUNOCONJUGATES, AND USES THEREOF | IL2, CD47, EPCAM | GPR119 3159/4885MAPT 4070/4885PTPN11 2213/4885 |
| US-20020037900-A1 | Hydroxamic acid derivatives | ADAM17, ADAM10, ADAM33 | GPR119 4313/4885MAPT 1206/4885PTPN11 4473/4885 |
| US-20030216404-A1 | Hydroxamic acid derivatives | ADAM17, ADAM10, ADAM33 | GPR119 4313/4885MAPT 1206/4885PTPN11 4473/4885 |
| US-12398130-B2 | Acid addition salts of piperazine derivatives | DNPEP, GAA, SLC30A5 | GPR119 2242/4885MAPT 3165/4885PTPN11 1570/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.